Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03537768 |
|
Recruitment Status : Unknown
Verified October 2019 by Health Decisions.
Recruitment status was: Recruiting
First Posted : May 25, 2018
Last Update Posted : October 8, 2019
|
Sponsor:
Health Decisions
Collaborator:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Information provided by (Responsible Party):
Health Decisions
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The proposed research study is a Phase IIb, multi-center, single-blind, randomized study of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg to evaluate EC effectiveness in women with weight ≥ 80 kg who present within 72 hours of unprotected intercourse.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Contraception | Drug: Ulipristal Acetate Drug: Levonorgestrel | Phase 4 |
Orally-dosed emergency contraception (EC) is highly effective when used properly. EC is up to 90% effective at preventing pregnancy following unprotected intercourse. Both ulipristal acetate (UPA) and levonorgestrel (LNG) delay or inhibit ovulation when used for EC. For individual women, use of EC provides a critical backup to prevent unintended pregnancy.
However, obesity may severely impair EC effectiveness. Data from two large randomized control trials to identify risk factors for EC failure. A woman of obese body mass index (BMI) (≥30mg/kg2) using LNG-based EC had more than a 4 times greater risk of pregnancy compared to her normal BMI counterpart and a woman of overweight BMI (25-29.9) was at twice the risk of pregnancy. Failure was also associated with a high body weight. LNG-based EC appears to have a ceiling of efficacy at 70 kg and no efficacy for women 80 kg and above. It is believed that by doubling the dose to LNG 3.0 mg, serum levels of LNG are corrected to a therapeutic range.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 1200 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Prevention |
| Official Title: | A Multi-center, Randomized Study of the Efficacy of Ulipristal Acetate (UPA) 30 mg, Levonorgestrel (LNG) 1.5 mg, and LNG 3.0 mg for Emergency Contraception (EC) in Women With Weight ≥ 80 kg |
| Actual Study Start Date : | July 12, 2018 |
| Estimated Primary Completion Date : | July 31, 2020 |
| Estimated Study Completion Date : | September 30, 2020 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
| Active Comparator: UPA 30mg |
Drug: Ulipristal Acetate
UPA Tablet
Other Name: Ella |
| Active Comparator: LNG 1.5 mg |
Drug: Levonorgestrel
LNG Tablet
Other Name: Plan B |
| Active Comparator: LNG 3.0 |
Drug: Levonorgestrel
LNG Tablet (x2)
Other Name: Plan B (double dose) |
Primary Outcome Measures :
- Incidence of pregnancies of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg in women with weight ≥ 80 kg for emergency contraception (within 72 hours of unprotected intercourse). [ Time Frame: 1-3 months ]
Secondary Outcome Measures :
- Incidence of treatment emergent adverse events of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg in women with weight ≥80 kg seeking emergency contraception. [ Time Frame: 1-3 months ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 40 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Be in good general overall health with no chronic medical conditions that result in periodic exacerbations that require significant medical care.
- Between 18 and 40 years inclusive at the enrollment visit.
- Weight ≥ 80 kg.
- Have regular menstrual cycles that typically occur every 21-35 days when not using hormonal contraception.
- If subject is postpartum or post-abortal, she must have experienced a menstrual bleed since the pregnancy ended
- If a subject recently used non-injectable hormonal contraception, one bleeding episode consistent with menses must have occurred since last use;
- Willing to avoid use of any hormonal or intrauterine contraception until the end of the study;
- For women with a recent history of Depo Provera use, the most recent injection must have been at least 6 months before study entry, and the subject must have had at least one normal menstrual cycle (2 consecutive menses);
- Request emergency contraception within 72 hours (3 days) after unprotected coitus, as defined by lack of contraceptive use, condom breakage (including condoms lubricated with spermicide), or other barrier contraceptive method failure;
- Have a negative urine pregnancy test at time of screening
- Reports all acts of unprotected coitus since her prior menses are within 72 hours prior to enrollment;
- Willing to abstain from further acts of unprotected intercourse until the end of the study;
- Give voluntary, written informed consent, and agree to observe all study requirements including being available for follow up for at least the next 4 weeks;
- Accepts that the risk of pregnancy with oral EC is greater than that following placement of a copper IUD for EC.
Exclusion Criteria:
- Be currently pregnant (positive high-sensitivity urine pregnancy test);
- Be currently breastfeeding or within 30 days of discontinuing breastfeeding, unless the subject has already had a menses following discontinuation of breastfeeding;
- Desire to use hormonal systemic contraception within 5 days of study drug use
- Have had a female sterilization procedure;
- Have a partner with a history of vasectomy;
- Current inability to tolerate oral medication;
- Have impaired hypothalamic-pituitary-adrenal reserve or oral glucocorticoid replacement therapy in the last year.
- Have known liver disease;
- Have known liver abnormalities with elevated enzymes at least twice the upper limit of normal requiring use of liver enzyme inducers.
- Have known hypersensitivity to the active substance UPA or LNG, or any of the excipients of the study treatment.
- Have a current need for exogenous hormones.
- Have concomitant use of strong CYP3A4 inhibitors (as identified by the FDA) or inducers at the time of or planned use within 3 days of dosing;
- Use any medications that can interfere with the metabolism of hormonal contraceptives; take antibiotics that can interfere with metabolism of hormonal contraceptives at the time of or planned use within 3 days of dosing of the study drug; or use any drugs designated by the FDA as falling in the Pregnancy and Lactation narrative subsections (formerly Category D or X medications).
- Current or recent (within one month) participation in any other trial of an investigational medicine or device or planning to participate in another clinical trial during this study.
- Have a history of a bariatric surgery procedure associated with malabsorption.
- Live outside of the catchment area of the study site.
- Have used UPA or LNG EC within 30 days prior to enrollment and not had a menses since using the drug.
- Be a site staff member with delegated study responsibilities or a family member of a site staff member with delegated study responsibilities. -
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03537768
Contacts
| Contact: Amber Blackmon | 919-967-1111 ext 117 | sblackmon@healthdec.com |
Locations
Show 18 study locations
Sponsors and Collaborators
Health Decisions
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Investigators
| Study Director: | Diana Blithe, PhD | NICHD Director |
| Responsible Party: | Health Decisions |
| ClinicalTrials.gov Identifier: | NCT03537768 |
| Other Study ID Numbers: |
CCN013C |
| First Posted: | May 25, 2018 Key Record Dates |
| Last Update Posted: | October 8, 2019 |
| Last Verified: | October 2019 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
| Product Manufactured in and Exported from the U.S.: | Yes |
Additional relevant MeSH terms:
|
Emergencies Disease Attributes Pathologic Processes Levonorgestrel Ulipristal acetate Contraceptive Agents, Hormonal |
Contraceptive Agents Reproductive Control Agents Physiological Effects of Drugs Contraceptive Agents, Female Contraceptives, Oral, Synthetic Contraceptives, Oral |